JAKARTA – The loss recorded by PT Dosni Roha Indonesia Tbk (ZBRA) swelled 179% year-on-year (yoy) in H1 2024 to IDR 166.11 billion from the initial IDR 59.52 billion seen in H1 2023. This resulted from significant decrease in its revenue.

Based on Financial Report of H1 2024 quoted Wednesday (2/10), the revenue of this Tanoesoedibjo-owned venture was reported at IDR 338.29 billion, declining heavily from IDR 793.30 billion in H1 2023.

Then, its gross profit also plummeted 69% yoy to IDR 37.73 billion in H1 2024 from IDR 121.67 billion, bringing the gross profit margin down to 11.15% from 15.33% seen in H1 2023.

ZBRA’s revenue came from sales of medical equipment of IDR 133.88 billion, down from IDR 283.84 billion; e-commerce sales of IDR 24.27 billion, down from IDR 92.31 billion; drugs sales of IDR 29.52 billion, down from IDR 133.62 billion; consumer healthcare of IDR 10 billion, down from IDR 73.82 billion; supplement sales of IDR 9.31 billion, down from IDR 17.08 billion; gas sales of none from the previous IDR 8.05 billion; and others of IDR 3.14 billion, plummeting from IDR 184.54 billion.

Its operating loss was reported at IDR 114.10 billion from the initial operating profit of IDR 2.22 billion. Thankfully, the company saw optimisation in the factors leading to the loss, as seen in decreased selling expenses, general and administrative expenses, as well as gains/losses from forex, and other income. (LK/ZH)